|52 Week Rng||-|
|P/E Ratio (TTM)||-|
|P/E Ratio (Fwd)||-|
|Div & Yield||-|
Helthcare, biotechnology industry, long position. Good revenue growth: 12.66% over the past four years. Very strong EBIT average rate over the past four years of 38.71%. High ROE (average of 22.84%). High Price/Book ratio of 2.22, which indicates a growth stock. Pays no dividends. The stock has beta of 2.58 in accordance with our strategy target portfolio beta (1-1.4).
Cambrex Corporation is an innovative life sciences company with a focus on active pharmaceutical ingredient (API) development and manufacturing. Profitable, growing, small cap and PE < 15.